Zealand Pharma's High-Stakes Pitch: Moving Beyond the GLP-1 Obesity Hype

COPENHAGEN, Denmark – November 09, 2026 — When Zealand Pharma A/S Chief Executive Officer Adam Steensberg takes the stage at the Jefferies Global Healthcare Conference in London next Monday, he will be stepping into a markedly different obesity market than the one that existed just a year ago. The era of unquestioned GLP-1 exuberance is giving way to a more pragmatic phase of clinical execution. For investors and healthcare systems alike, the focus has shifted from sheer weight loss percentages to tolerability, lean mass preservation, and the management of complex comorbidities.

Zealand Pharma, a Danish biotechnology firm with a 25-year pedigree in peptide research, announced today that Steensberg will participate in a November 16 fireside chat. The timing is impeccable. As the market giants—Novo Nordisk and Eli Lilly—prepare their next generation of oral therapies and dual-agonists for a 2026 rollout, Zealand is attempting to outflank them not by mimicking their mechanisms, but by commercializing alternative biological pathways.

The Amylin Advantage: Tolerability as a Market Differentiator

The dominant narrative in metabolic health has been monopolized by GLP-1 receptor agonists. While undeniably effective, these therapies are plagued by a hidden execution challenge: patient retention. High rates of gastrointestinal adverse events often lead to treatment discontinuation in real-world settings, transforming a clinical miracle into a logistical headache for payers and providers.

This is where Zealand Pharma's lead candidate, petrelintide, enters the equation. Developed in collaboration with Roche, petrelintide is a long-acting amylin analog. Rather than primarily suppressing appetite through the GLP-1 pathway, it activates amylin receptors to induce satiety, slow gastric emptying, and suppress glucagon secretion. Early animal models and clinical data suggest it may also help preserve lean muscle mass—a critical metric as the medical community grows increasingly concerned about the frailty risks associated with rapid, indiscriminate weight loss.

"The holy grail in the next wave of obesity therapeutics isn't just matching the fifteen to twenty percent weight loss of the incretins, but doing so with a profile that keeps patients on the drug," noted one healthcare equity analyst familiar with the company's pipeline. "Placebo-like tolerability is the new efficacy."

Zealand's execution on petrelintide has been methodical. In the first half of 2026, the Phase 2 ZUPREME-1 trial demonstrated up to 10.7% mean weight loss at 42 weeks with remarkably low rates of gastrointestinal side effects and zero discontinuations due to vomiting at the highest doses. This was followed by October's ZUPREME-2 data in type 2 diabetics, showing a 9.2% body weight reduction and clinically relevant HbA1c reductions.

Moving from pilot to production, the company initiated the global Phase 3 ZUPREME program in September 2026. Enrolling approximately 7,000 participants across three trials, this registrational program is the ultimate stress test for petrelintide's commercial viability. Furthermore, a Phase 2 trial exploring a fixed-dose combination of petrelintide with Roche’s GLP-1/GIP dual agonist, enicepatide (CT-388), is slated for the second half of this year, aiming to combine the tolerability of amylin with the brute force of dual incretins.

The Survodutide Reality Check: Navigating the MASH Niche

If petrelintide represents Zealand's broad-market ambition, its other late-stage asset, survodutide, offers a sobering lesson in the realities of clinical development. Licensed to Boehringer Ingelheim, survodutide is a glucagon/GLP-1 receptor dual agonist.

Just today, Zealand and Boehringer Ingelheim released data from the SYNCHRONIZE-CVOT trial. While the drug successfully demonstrated a favorable cardiovascular safety profile—proving it does not increase the risk of major cardiovascular events compared to a placebo—the efficacy data triggered a sharp market reaction. The up to 9.8% weight loss reported was viewed as inferior to the high-teens percentages routinely posted by Eli Lilly's tirzepatide and Novo's advanced pipeline. Consequently, Zealand's shares took a hit in early trading.

However, viewing survodutide solely through the lens of generic obesity misses the strategic nuance of its mechanism. The addition of glucagon agonism provides a distinct, liver-focused advantage by promoting direct lipolysis and efficient lipid processing. This makes survodutide a highly targeted weapon against metabolic dysfunction-associated steatohepatitis (MASH).

In earlier Phase 2 trials, 83% of high-dose participants achieved MASH resolution, earning the drug both Fast Track and Breakthrough Therapy Designations from the U.S. FDA. Boehringer Ingelheim is currently aggressively advancing the LIVERAGE and LIVERAGE-Cirrhosis Phase 3 trials. In the ruthless calculus of pharmaceutical execution, survodutide may not win the vanity metric of total body weight reduction, but it is uniquely positioned to dominate the lucrative, high-need niche of liver-related metabolic disease.

The Partnering Equation: Execution at Global Scale

A recurring theme in the biotechnology sector is the failure of innovative R&D firms to cross the commercialization chasm. Building a global supply chain, funding 7,000-patient Phase 3 trials, and navigating international regulatory labyrinths routinely bankrupts mid-cap innovators.

Zealand Pharma has mitigated this risk through a masterclass in strategic partnering. The company's business model separates the high-risk, high-reward discovery phase from the capital-intensive late-stage execution.

The Roche collaboration for petrelintide, signed in early 2025, is a prime example. The agreement, worth up to $5.3 billion, included a massive upfront payment that fundamentally transformed Zealand's balance sheet. As of mid-2026, the company reported a formidable cash position of DKK 14.5 billion (approximately $2.07 billion). This capital reserve provides a massive operational runway, shielding the company from the volatile biotech capital markets and allowing it to fund its proprietary early-stage pipeline without diluting shareholders.

Similarly, Boehringer Ingelheim assumes the entirety of the global development and commercialization costs for survodutide. Zealand retains eligibility for up to €315 million in outstanding milestone payments and tiered royalties on potential global sales. By outsourcing the heavy lifting of late-stage execution to pharmaceutical titans with entrenched manufacturing and distribution networks, Zealand ensures its molecules have a realistic path to patients.

The Road Ahead: What Investors Want to Hear

When Steensberg sits down at the Jefferies conference next week, institutional investors will be listening for more than just a recitation of clinical milestones. They will be looking for a cohesive narrative that reconciles today's survodutide data with the broader, multi-billion-dollar potential of the amylin portfolio.

The executive will need to articulate how Zealand Pharma plans to maintain its momentum in an environment where oral GLP-1 formulations are expected to hit the market in early 2026, drastically lowering the barrier to entry for obesity treatments. The market will demand clarity on the enrollment velocity of the Phase 3 ZUPREME trials and the strategic timeline for the petrelintide combination study.

Ultimately, the obesity market is transitioning from a gold rush of early-stage discovery to an industrial era of scaled manufacturing, specialized indications, and patient retention. Zealand Pharma has the capital, the partnerships, and the differentiated pipeline to compete in this new paradigm. The challenge for Steensberg in London will be proving that his company can execute on the clinical promises of its peptide platform, translating innovative science into sustainable, commercial reality.